Abstract:Abstract: OBJECTIVE To evaluate the surveillance data of adverse events following immunization (AEFI) of human papilloma virus (HPV) vaccines among adults (≥18 years old) in Suzhou from 2018 to 2023, and to provide data support for the safety monitor⁃ ing of multiple HPV vaccines. METHODS The AEFI caused by the 2-valent vaccines, 4-valent vaccines, and 9-valent vaccines?in Suzhou from 2018 to 2023 were screened through the Chinese Disease Control of immunization information management system. The vaccination data in Suzhou from 2018 to 2023 were collected by the adult module of Jiangsu province vaccination integrated service management information system for the basic distribution and classification of AEFI. RESULTS The overall of AEFI reported after HPV vaccination was 215 among adults in Suzhou from 2018 to 2023, with a reported incidence of 13.76/10 5 doses, of which 207 cases (97.28%) were general reactions. There was no significant difference in the reported incidence of AEFI for the 2-valent vac⁃ cines, 4-valent vaccines, and 9-valent vaccines. According to the basic situation of AEFI, the majority of AEFI were aged between 35 and 39 (25.12%), the most were reported in the second quarter (30.70%), and the most were reported in the first dose (42.33%). The main clinical manifestations were fever (57 cases), local redness (97 cases) and local induration (54 cases). AEFI of the 2-valent vaccines, 4-valent vaccines, and 9-valent vaccines occurred within 1 day after vaccination in 82.35%, 89.09% and 79.35%, respec⁃ tively. CONCLUSION The safety of HPV vaccine among adults in Suzhou from 2018 to 2023 was high, and all medical institutions still maintain the sensitivity of reporting.